Lanreotide (Somatuline Autogel) in Thyroid-associated Ophthalmopathy Treatment

Inclusion Criteria: * Patients with autoimmune thyroid disease and whose centre's medical records confirm the presence of euthyroidism for at least two months before being included into the study * Thyroid-associated ophthalmopathy diagnosed a minimum of six months before his/her participation in the study, well documented in the centre's medical records and based on the moderate intensity of thyroid-associated ophthalmopathy in the worst eye * Patients whose ophthalmopathy activity has been demonstrated by a positive octreoscan Exclusion Criteria: * The patient presents compressive optical neuropathy signs which require immediate surgical treatment or suffers from serious intensity thyroid ophthalmopathy * The patient has been treated with radio-iodine for his/her thyroid disturbance in the past 6 months * The patient's thyroid-associated ophthalmopathy has been treated previously (except for drops and local measures) or is planned to be treated with radio-iodine or thyroidectomy for his/her autoimmune thyroid disease during the study or suffers from myopia, glaucoma or any other eye disease which could modify the ophthalmological progress * The patient is a smoker of more than 5 cigarettes per day